Drug-Eluting Balloon Catheters Market Companies, Strategic Expansion Initiatives, Revenue Diversification and Strategic Joint Ventures

Drug-Eluting Balloon Catheters Market Leading Companies

• Abbott
• B. Braun Melsungen AG
• Bard/BD Interventional
• BIOTRONIK
• Boston Scientific
• Concept Medical
• Cook Medical
• Edward Lifesciences
• Gore & Associates
• Lépine
• MedAlliance
• Medtronic
• Philips
• Terumo Corporation
• W. L. Gore & Associates

Drug-Eluting Balloon Catheters Market Growth:

The global drug-eluting balloon catheters market size is calculated at US$ 1.42 billion in 2024, grew to US$ 1.58 billion in 2025, and is projected to reach around US$ 4.02 billion by 2034. The market is expanding at a CAGR of 11.1% between 2025 and 2034.

Trends in the Drug-Eluting Balloon Catheters Market

Numerous leaders are leveraging their position in the global market to invest in the development of novel therapies and the latest solutions for severe conditions.

• In September 2025, Concept Medical Group, a global player in drug-delivery technologies, acquired commercial approval for its flagship MagicTouch Sirolimus-Coated Balloon (SCB) for CAD treatment from ANVISA, Brazil’s Health Surveillance Agency.
• In February 2025, Teleflex Incorporated, a leading global provider of medical technologies, entered into a definitive agreement to acquire substantially all of the Vascular Intervention business of BIOTRONIK SE & Co. KG for a predicted cash payment on closing of approximately €760 million.
• In August 2023, Advanced NanoTherapies received $4M Series A extension from an undisclosed strategic investor for drug-coated balloon development.

Latest Announcements by Industry Leaders

In April 2025, Cordis, a leading player in interventional cardiovascular and endovascular technologies, announced new data from two important peripheral studies that are assessing the SELUTION SLR™ Drug-Eluting Balloon (DEB). Dr. Michael Lichtenberg, Chief of Interventional Angiology, said that this approach will deliver unequivocal clinical advantages in complex patient cohorts.

Recent Developments in the Drug-Eluting Balloon Catheters Market

• In February 2025, Cagent Vascular, Inc., the exclusive developer of serration technology for vessel dilation in endovascular interventions, launched its novel product, Serranator SL-PRO™ PTA Serration Balloon Catheter.
• In March 2024, Boston Scientific Corporation received U.S. Food and Drug Administration (FDA) approval for the AGENT™ Drug-Coated Balloon (DCB), which is used in treating coronary in-stent restenosis (ISR) in patients with coronary artery disease.

Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com